Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


The problem of the "optimal pharmacotherapy" choice in patients with stable coronary artery disease is discussed. Expert’s opinions are presented concerning first-line antiischemic drugs and about current approaches to the choosing additional (adjuvant) antiischemic drugs. The practical application of optimal pharmacotherapy in patients with stable angina pectoris is also discussed.

About the Authors

S. R. Gilyarevskiy
Research Institute of Emergency Medicine named after N.V. Sklifosovsky
Russian Federation

V. A. Orlov
Russian Medical Academy of Postgraduate Education
Russian Federation

I. M. Kuz'mina
Research Institute of Emergency Medicine named after N.V. Sklifosovsky
Russian Federation


1. The management of stable angina. NICE clinical guideline 126, published on 27 July 2011. Available at: Date of access: 15.06.2012.

2. Henderson R.A., O'Flynn N. Guideline Development Group. Management of stable angina: summary of NICE guidance. Heart 2012;98:500–507.

3. Sculpher M.J., Petticrew M., Kelland J.L., et al. Resource allocation for chronic stable angina: a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions. Health Technol Assess 1998;2:1e175.

4. Scottish Intercollegiate Guidelines Network. Management of Stable Angina. Edinburgh: NHS Quality Improvement Scotland; 2007.

5. Fox K.M., Garcia M.A., Ardissino D. Guidelines on the management of stable angina pectoris. Eur Heart J 2006;27:1341–1381.

6. von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J Am Coll Cardiol 1995; 25:231–238.

7. van Dijk R.B., Lie K.I., Crijns H.J. Diltiazem in comparison with metoprolol in stable angina pectoris. Eur Heart J 1988;9:1194–1199.

8. O'Hara M.J., Khurmi N.S., Bowles M.J., et al. Diltiazem and propranolol combination for the treatment of chronic stable angina pectoris. Clin Cardiol 1987;10:115–123.

9. Kawanishi D.T., Reid C.L., Morrison E.C., et al. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol 1992;19:409–417.

10. Savonitto S., Ardissiono D., Egstrup K., et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996;27:311–316.

11. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805–2816.

12. Rehnqvist N., Hjemdahl P., Billing E., et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17:76–81.

13. Dargie H.J., Ford I, Fox K.M. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996;17:104–112.

14. Hjemdahl P., Eriksson S.V., Held C., et al. Favourable long term prognosis in stable angina pectoris: an extended follow up of the Angina Prognosis Study in Stockholm (APSIS). Heart 2006;92:177–182.

15. Shu D.F., Dong B.R., Lin X.F., et al. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil 2012;19:330–341.

16. Daly C.A., Clemens F., Sendon J.L.L., et al. The initial management of stable angina in Europe, from the Euro Heart Survey. Eur Heart J 2005;26:1011–1022.

17. de Vries R.J., Dunselman P.H., van Veldhuisen D.J., et al. Comparison between felodipine and isosor-bide mononitrate as adjunct to beta blockade in patients >65 years of age with angina pectoris. Am J Cardiol 1994;74:1201–1206.

18. Gori T., Parker J.D. Nitrate-induced toxicity and preconditioning: a rationale for reconsidering the use of these drugs. J Am Coll Cardiol 2008;52:251–254.

19. DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 2006;53:399–406.

20. Savelieva I., Camm A.J. If inhibition with ivabradine: electrophysiological effects and safety. Drug Saf 2008;31:95–107.

21. Tardif J.C., Ford I., Tendera M., et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529–2536.

22. Ruzyllo W., Tendera M., Ford I., et al. Antianginal efficacy and safety of ivabradine compared with am-lodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multi-centre, noninferiority trial. Drugs 2007;67:393–405.

23. Tardif J.C., Ponikowski P., Kahan T., et al. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009;30:540–548.

24. Meeter K., Kelder J.C., Tijssen J.G., et al. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. J Cardiovasc Pharmacol 1992;(20 Suppl 3):S59–66.

25. Ulvenstam G., Diderholm E., Frithz G., et al. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, ran-domized, multicenter study. J Cardiovasc Pharmacol 1992;(20 Suppl 3):S67–73.

26. Guermonprez J.L., Blin P., Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993;14(Suppl B):S30–34.

27. Chatterjee T., Fleisch M., Meier B., et al. Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol 1999;2:213–217.

28. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269–1275.

29. Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309–316.

30. Stone P.H., Gratsiansky N.A., Blokhin A., et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566–575.

31. Szwed H., Sadowski Z., Elikowski W., et al. Combination treatment in stable effort angina using trimetazi-dine and metoprolol: results of a randomized, double-blind, multicenter study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001;22:2267—2274.

32. Chazov E.I., Lepakchin V.K., Zharova E.A., et al. Trimetazidine in Angina Combination Therapy--the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005;12:35—42.

33. Herman M., Donovan J., Tran M., et al. Use of beta-blockers and effects on heart rate and blood pressure post-acute coronary syndromes: are we on target? Am Heart J 2009;158:378–385.

34. Jabbour A., Macdonald P.S., Keogh A.M., et al. Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease J Am Coll Cardiol 2010;55:1780– 1787.

35. Yusuf S., Islam S., Chow C.K., et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231–1243.

36. Haas J.S., Phillips K.A., Gerstenberger E.P., Seger A.C. Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997–2000. Ann Intern Med 2005;142:891–897.

37. Martsevich S.Yu., Kutishenko N.P., Ginzburg M.L. The KARDIOKANON study: a way to settle the subject of clinical equivalence of generic and original drugs. Rational Pharmacother Card 2012;8(2):179–184. Russian (Марцевич С.Ю., Кутишенко Н.П., Гинзбург М.Л., и др. Исследование КАРДИОКАНОН: способ решения вопроса о клинической эквивалентности оригинальных и воспроизведенных препаратов. Рациональная Фармакотерапия в Кардиологии 2012;8(2):179–184).

For citation:

Gilyarevskiy S.R., Orlov V.A., Kuz'mina I.M. THE PROBLEM OF THE OPTIMAL PHARMACOTHERAPY CHOICE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE. Rational Pharmacotherapy in Cardiology. 2012;8(3):457-462. (In Russ.)

Views: 393

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)